63 completed, 37 recruiting, 33 terminated, 25 active not recruiting. 92 Phase 2, 73 Phase 1, 13 Not applicable, 6 Phase 3, 3 Early Phase 1.
Follow Polyomavirus Infections: new trials by email Literature Review of Polyomavirus Infections trials Research Report on Polyomavirus Infections
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Low Dose, Reduced Frequency Nivolumab for the Treatment of Unresectable or Metastatic Cancer, AFFORD IO Trial Biospecimen Collection, Computed Tomography, Magnetic Resonance Imaging - Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage III Cutaneous Merkel Cell Carcinoma AJCC v8 | Phase 2 | Not yet recruiting | Fred Hutchinson Cancer Center | 50 | 2026-12-01 | 2026-09-17 |
| ASTX727 & Retifanlimab-dlwr for Advanced Merkel Cell After Progression on Anti-PD-(L)1 ASTX727 + retifanlimab - Merkel Cell Carcinoma, Merkel Cell Carcinoma, Stage III | Phase 1 / Phase 2 | Not yet recruiting | University of Wisconsin, Madison | 31 | 2026-10-01 | 2026-09-29 |
| A Study to Evaluate ARV-6723 Alone and With Pembrolizumab in Participants With Advanced Solid Tumors ARV-6723, Pembrolizumab, SOC - Advanced Solid Tumor | Phase 1 / Phase 2 | Recruiting | Arvinas Inc. | 499 | 2026-07-29 | 2026-10-13 |
| A Study of Pembrolizumab in Japanese Pediatric Participants With Solid Tumors or Lymphomas and Japanese Adult Participants With Merkel Cell Carcinoma (MK-3475-G21/KEYNOTE-G21) Pembrolizumab - Malignant Neoplasm, Carcinoma, Merkel Cell | Phase 1 / Phase 2 | Recruiting | Merck Sharp & Dohme LLC | 20 | 2026-06-23 | 2026-07-13 |
| Intravenous Brincidofovir as an Antiviral for Treatment of Progressive Multifocal Leukoencephalopathy: A Pilot Study Brincidofovir - Progressive Multifocal Leukoencephalopathy | Phase 2 | Recruiting | National Institute of Neurological Disorders and Stroke (NINDS) | 24 | 2026-06-05 | 2026-07-22 |
| Risk of Progressive Multifocal Leukoencephalopathy Among Patients With Multiple Sclerosis Exposed to Zeposia Ozanimod - Multiple Sclerosis, Progressive Multifocal Leukoencephalopathy | Recruiting | Bristol-Myers Squibb | 15 | 2026-06-04 | 2026-07-29 | |
| Neoadjuvant Merkel Cell Carcinoma Therapy (Tx) With the PD-1 Inhibitor Cemiplimab Cemiplimab 350 mg i.v. on day 1 of every 21 days cycle for 2 cycles, Placebo NaCl 0.9% solution i.v. on day 1 of every 21 days cycle for 2 cycles. - Merkel Cell Carcinoma, Stage I, Merkel Cell Carcinoma, Stage II | Phase 2 | Recruiting | Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest | 135 | 2026-05-29 | 2026-06-22 |
| TIL Therapy in cSCC and MCC LN-145, Cyclophosphamide, Fludarabine - Cutaneous Squamous Cell Carcinoma, Merkel Cell Carcinoma | Phase 2 | Recruiting | Karam Khaddour, MD, MS | 14 | 2026-02-10 | 2026-02-13 |
| T-cell Therapy in Patients With PML Application of T-lymphocytes - Progressive Multifocal Leucoencephalopathy (PML) | Phase 2 | Recruiting | Hannover Medical School | 23 | 2026-02-06 | 2026-10-15 |
| IFx-Hu2.0 As An Adjunctive Therapy To Pembrolizumab In Advanced Or Metastatic Merkel Cell Carcinoma (MCC) IFx-Hu2.0, Pembrolizumab - Advanced Or Metastatic Merkel Cell Carcinoma | Phase 1 | Recruiting | TuHURA Biosciences, Inc. | 9 | 2026-01-27 | 2026-10-21 |
| The Cancer Connected Access and Remote Expertise Beyond Walls Program to Provide In-Home Cancer Treatment and Improve Treatment Satisfaction in Cancer Patients Living in the Florida Panhandle and Surrounding Areas Cancer Therapeutic Procedure, Questionnaire Administration - Amyloidosis, Basal Cell Carcinoma | Phase 2 | Recruiting | Mayo Clinic | 27 | 2025-12-18 | 2026-09-30 |
| Placebo-Controlled Trial of IFx-Hu2.0 Followed By Pembrolizumab In Checkpoint Inhibitor Naïve Participants With Advanced Or Metastatic Merkel Cell Carcinoma IFx-Hu2.0, Placebo, Pembrolizumab - Advanced Or Metastatic Merkel Cell Carcinoma | Phase 2 / Phase 3 | Recruiting | TuHURA Biosciences, Inc. | 118 | 2025-12-11 | 2026-04-17 |
| Artificial Intelligence Model for Renal Allograft Rejection Identification, Lesion Quantification and Rejection Risk Prediction Based on Prospective Renal Transplant Pathology and Clinical Multidimensional Data Graft Rejection, Kidney Transplantation | Active not recruiting | Chen Dajin | 1000 | 2025-11-01 | 2026-08-03 | |
| Phase I Study of [225Ac]Ac-ETN029 in Patients With Advanced DLL3-expressing Solid Tumors 225Ac-ETN029, 111In-ETN029 - Small Cell Lung Carcinoma, Large Cell Neuroendocrine Carcinoma of the Lung | Phase 1 | Recruiting | Novartis Pharmaceuticals | 116 | 2025-10-16 | 2026-09-22 |
| Radiation Combined With BIspecific T-Cell Engager in DLL3 Expressing Tumors Tarlatamab, Concurrent Radiation Therapy, Sequential Radiation therapy - Melanoma, Medullary Thyroid Cancer | Phase 1 / Phase 2 | Recruiting | University of Arizona | 30 | 2025-09-08 | 2026-10-06 |
| A Study to Investigate Safety of AZD6750 in Adult Participants With Select Advanced or Metastatic Solid Tumors AZD6750, rilvegostomig - Melanoma, Non-small Cell Lung Cancer | Phase 1 / Phase 2 | Recruiting | AstraZeneca | 120 | 2025-07-29 | 2026-10-08 |
| Electrochemotherapy (ECT) in Patients With Primary Visceral Tumors and/or Secondary Visceral Localizations, of Any Histotype percutaneous, laparoscopic or laparotomy lesion electrochemotherapy - Primary Visceral Tumors of Any Histotype, Visceral Lesions | Not applicable | Recruiting | Istituto Oncologico Veneto IRCCS | 24 | 2025-07-23 | 2026-04-13 |
| Study of 225Ac-SS0110 in Subjects With ES-SCLC or MCC (SANTANA-225 ) 225Ac-SSO110 + SoC, Atezolizumab, Durvalumab - Small Cell Lung Cancer Extensive Stage, Merkel Cell Carcinoma | Phase 1 / Phase 2 | Terminated | Ariceum Therapeutics GmbH | 2 | 2025-07-01 | 2026-02-05 |
| Exploring Merkel Cell Carcinoma Clinical Trial Engagement Patterns Merkel Cell Carcinoma | Not yet recruiting | Power Life Sciences Inc. | 500 | 2024-10-01 | 2023-09-15 | |
| Immunotherapy in Combination With Prednisone and Sirolimus for Kidney Transplant Recipients With Unresectable or Metastatic Skin Cancer Biopsy Procedure, Biospecimen Collection, Computed Tomography - Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage III Cutaneous Merkel Cell Carcinoma AJCC v8 | Phase 1 / Phase 2 | Recruiting | National Cancer Institute (NCI) | 16 | 2024-07-24 | 2026-10-14 |
Showing 20 of 180. Sign in to see all of them.
Carcinoma, Merkel Cell (147) · Melanoma (61) · Carcinoma, Non-Small-Cell Lung (37) · Carcinoma, Renal Cell (36) · Uterine Cervical Neoplasms (30) · Leukoencephalopathy, Progressive Multifocal (29) · Small Cell Lung Carcinoma (28) · Stomach Neoplasms (28) · Carcinoma, Hepatocellular (25) · Carcinoma, Transitional Cell (25) · Squamous Cell Carcinoma of Head and Neck (23) · Triple Negative Breast Neoplasms (22) · Neoplasm Metastasis (21) · Carcinoma, Basal Cell (20) · Skin Neoplasms (17)
DNA Virus Infections (180) · Infections (180) · Virus Diseases (180) · Adenocarcinoma (147) · Neoplasms by Histologic Type (147) · Neoplasms, Germ Cell and Embryonal (147) · Neoplasms, Glandular and Epithelial (147) · Neoplasms, Nerve Tissue (147) · Neuroectodermal Tumors (147) · Tumor Virus Infections (147) · Carcinoma, Neuroendocrine (144) · Carcinoma (142) · Neuroendocrine Tumors (141) · Neoplasms (131)
pembrolizumab (32) · avelumab (21) · Nivolumab (20) · Ipilimumab (10) · Cyclophosphamide (9) · Radiotherapy (9) · atezolizumab (8) · cemiplimab (7) · Specimen Handling (6) · fludarabine (6) · Biopsy (5) · Interleukin-2 (5) · Magnetic Resonance Spectroscopy (5) · Radiation (5) · aldesleukin (5)
National Cancer Institute (NCI) (10) · Biogen (5) · Memorial Sloan Kettering Cancer Center (5) · National Institute of Neurological Disorders and Stroke (NINDS) (5) · Fate Therapeutics (4) · Fred Hutchinson Cancer Center (4) · H. Lee Moffitt Cancer Center and Research Institute (4) · ImmunityBio, Inc. (4) · Incyte Biosciences International Sàrl (4) · Incyte Corporation (4) · TuHURA Biosciences, Inc. (4) · M.D. Anderson Cancer Center (3) · Mayo Clinic (3) · 4SC AG (2) · AbbVie (2)
United States (128) · France (24) · Australia (20) · Spain (18) · Germany (15) · Italy (14) · Canada (11) · Belgium (8) · Japan (8) · United Kingdom (8) · Switzerland (6) · Netherlands (5) · Austria (4) · South Korea (4) · China (3)
Irene CM Cortese, M.D. (4) · Andrew S Brohl, MD (3) · Aude Chapuis (2) · Evan J Lipson (2) · John E. Janik, MD (2) · Paul Nghiem (2) · Robert Haddad, MD (2) · Shailender Bhatia (2) · Shailender Bhatia, MD (2)
PMID 42580817, PMID 21738597, PMID 21757257, PMID 23733308, PMID 24687904, PMID 25900182, PMID 27093365, PMID 27592805, PMID 29273043, PMID 29347993, PMID 29445030, PMID 29512061, PMID 29566106, PMID 29914528, PMID 30304652, PMID 30726175, PMID 31553054, PMID 31689874, PMID 32375680, PMID 32414862, PMID 32430019, PMID 32472503, PMID 32503950, PMID 32770720, PMID 32819975, PMID 32938212, PMID 33219092, PMID 33879601, PMID 33929874, PMID 34216247, PMID 34301810, PMID 34302788, PMID 34329846, PMID 34519839, PMID 34627593, PMID 34921021, PMID 35034046, PMID 35046056, PMID 35389428, PMID 35444059, PMID 35507536, PMID 36821617, PMID 37055772, PMID 37131154, PMID 37451295, PMID 37683276, PMID 37711623, PMID 37848259, PMID 37865395, PMID 38126779
2018 (5), P30CA015704 (5), 2023 (4), 2014 (3), 2016 (3), 2019 (3), K24CA139052 (2), U10CA032102 (2), UM1CA186691 (2), 2005 (1), N01CM62206 (1), N01CM62207 (1), P01CA225517 (1), P30CA016672 (1), R01CA176841 (1)